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EDITORIAL
Interactions between growth factors in the kidney:
Implications for progressive renal injury
Over the last decade there has been increasing interest the same cell line [8]. This is consistent with previous
in the role of growth factors in the development and pro- studies in fibroblasts demonstrating that, in contrast to
gression of renal disease. Growth factors have a diverse insulin, IGF-1 is able to induce VEGF production via
range of actions relevant to the kidney, including the regu- a phosphatidylinositol-3 (PI-3)/protein kinase B (PKB)
lation of cell morphology, apoptosis, and the production of independent process requiring mitogen-activated pro-
extracellular matrix (ECM). These observations, based tein (MAP) kinase activation [6]. Activation of Src/Raf/
initially on in vitro studies, have subsequently been con- MAP kinase pathways by a diverse range of mitogens
firmed with in vivo experiments using inhibitors of spe- and their receptors, including VEGF(R), PDGF(R), and
cific growth factors and their signaling pathways. For endothelin growth factor (EGF)(R) is known to modu-
example, insulin-like growth factor-1 (IGF-1), a mito- late a variety intracellular effects implicated in the patho-
genic growth factor regulated by growth hormone, is genesis of tissue injury [9]. These signaling pathways
locally up-regulated in the kidney in a variety of patho- are also important for other IGF-1–mediated effects,
logic conditions, including subtotal nephrectomy, high including cell proliferation and matrix production in re-
protein intake, and diabetes [1]. Vascular endothelial sponse to hyperglycemia or stretch. It remains to be
growth factor (VEGF), also known as vascular perme- determined what role Src plays in perpetuating the mito-
ability factor, is also up-regulated in the diabetic kidney genic effects of IGF-1 and VEGF in renal disease.
[2]. Furthermore, therapeutic approaches to block IGF-1 One must be cautious in extrapolating these in vitro
and VEGF production and/or action have been shown findings to the in vivo context of renal physiology and
experimentally to attenuate renal injury [1, 3]. in particular to pathophysiologic states. It is likely that
Over the last few years it has become increasingly a simple relationship linking IGF-1 to VEGF production
apparent that there are important interactions between does not fully describe their complex interaction in vivo.
growth factors that determine, in part, their diverse range While the mesangial cells constitutively express IGF-1
of activities. For example, many cell types secrete VEGF, receptors, VEGF is not constitutively expressed in these
and its expression is regulated by a number of other cells [10]. In addition, some studies are not consistent
growth factors and cytokines, including platelet-derived with VEGF expression as a downstream consequence of
growth factor (PDGF), basic fibroblast growth factor, IGF-1 receptor activation. For example, studies using
and transforming growth factor-. In this issue, Gruden IGF-1 receptor antagonists have failed to influence VEGF
et al [4] explore the relationship between IGF-1 and levels in the retina [11]. Furthermore, it may be the action
VEGF in mesangial cells. rather than the expression of VEGF, which is influenced
Studies have previously suggested a relationship be- by IGF-1. Specifically, in a model of retinal neovasculari-
tween IGF-I and VEGF. VEGF is thought to be a down- zation, VEGF-mediated activation of p44/42 MAP ki-
stream mediator of IGF-1 activity [5]. In addition, ex- nase appears to be partly mediated through IGF-1 [11].
pression of VEGF may be directly stimulated by IGF-I in It is likely over the next decade that therapies to inter-
various cell types, including fibroblasts, retinal pigment rupt IGF-1 and VEGF expression and/or signaling will
epithelial, and smooth muscle cell cultures [6, 7]. In the become available for clinical investigation. Indeed, trials
present study, Gruden et al [4] demonstrate that IGF-1 of agents, which modify the growth hormone–IGF-1 axis,
is also an important stimulus for VEGF production in are currently being explored in the context of diabetes
mesangial cells. and its complications. However, the complexity of the
Gruden et al [4] also describe a pivotal role for the interaction between these mediators emphasizes the dif-
nonreceptor tyrosine kinase Src, in IGF-1–mediated VEGF ficulty in predicting the ultimate efficacy of agents that
production, as had been reported by this group when modify only one growth factor. VEGF may be consid-
assessing an alternative stimulus, mechanical stress, in ered both protective (through stimulated angiogenesis)
and detrimental (through hypertrophy) even in the same
context, such as models of loss of renal mass. Further-Key words: growth factors, insulin-like growth factor-1, Src, vascular
endothelial growth factor. more, regional changes in growth factors do not appear
to be uniform in some disease states. For example, 2003 by the International Society of Nephrology
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